Sincere Co.,LTD. Q4 FY2024 earnings call

• Company Overview & Business Model

  • シンシア is a fabless contact lens manufacturer founded in 2008, outsourcing production to overseas partner factories and selling primarily to the Japanese market, focusing on safe, high-quality products at accessible prices across ophthalmic clinics, EC sites, and drugstores.
  • The firm is pursuing business diversification from its core contact lens operation, and has completed two acquisitions to date: a clinic consulting business in December 2022, and a POS system business for the reuse industry in November 2023, both of which contributed positively to FY2024 results. It also offers regulatory consulting services for overseas firms seeking Japan market approval for medical devices, quasi-drugs, and cosmetics, a high-growth potential new business.

• Core Contact Lens Business Performance

  • The flagship シンシアS series of silicone hydrogel contact lenses drove growth, with strong user demand for its high oxygen permeability and comfortable wear. The number of retail locations carrying the line has grown 1.2x over the past two years, and sales are now nearly 1.5x higher than two years ago.
  • While private label color lenses saw sales decline due to market changes, growth in シンシア branded lenses and private label clear lenses pushed the overall contact lens business to a year-over-year revenue increase.
  • In early February 2025, the company launched シンシアワンデー S 乱視用, a new toric lens addition to the シンシアS line that features industry-thinnest design and maintains the series' signature comfortable wear for long-time use.

• Overall FY2024 Financial Performance

  • Full year 2024 results: total revenue up 9.7% YoY to 6.539 billion yen, gross profit up 13.7% YoY to 2.096 billion yen, operating profit up 28.6% YoY to 484 million yen, ordinary profit up 4.8% YoY to 468 million yen, and net profit attributable to parent shareholders up 2.1% YoY to 301 million yen, achieving growth in both revenue and profit across all lines.
  • Profit margin expanded steadily over three years, driven by effective foreign exchange hedging, growth in high value-added silicone hydrogel products, and the addition of new acquired businesses.

1. Contact Lens Business: Revenue of 6.074 billion yen, segment profit of 628 million yen, contributing 92.9% of total consolidated revenue. 2. Consulting Business: Revenue of 60 million yen, segment profit of 30 million yen, contributing 0.9% of total consolidated revenue. 3. System Business (launched at the start of FY2024): Revenue of 405 million yen, segment profit of 57 million yen, contributing 6.2% of total consolidated revenue. A total adjustment of 232 million yen covers corporate shared costs such as management department expenses.

• For FY2025 (ending December 2025), management guides for 1.7% YoY revenue growth to 6.652 billion yen, with a projected decrease in profitability: gross profit down 5.4% YoY to 1.984 billion yen, operating profit down 44.7% YoY to 268 million yen, ordinary profit down 46.9% YoY to 248 million yen, and net profit attributable to parent shareholders down 48.4% YoY to 155 million yen, resulting in a forecast of top-line growth but bottom-line decline.
  • The profit decline projection is driven by expected higher cost ratios from the current unfavorable yen depreciation environment, partially offset by yen-denominated purchases for some products that reduce the impact of currency weakness.
  • Management prioritizes three key strategic initiatives for FY2025: 1) expanding product assortment to meet customer demand, anchored by the newly launched シンシアワンデー S 乱視用, 2) growing own-brand sales by strengthening ophthalmic clinic channels, raising drugstore brand awareness, and capturing growing inbound demand, 3) continuing to pursue new M&A while focusing on post-acquisition integration (PMI) of existing acquired businesses to improve profitability and capture group synergies.
  • For contact lens product categories, management projects sales growth for シンシア branded clear and color lenses driven by expanded marketing, while third-party supplied products are expected to remain under pressure from intensifying price competition.
  • Shareholder returns: A 19 yen per share dividend is planned for FY2024, following an update to the dividend policy to target a 30-40% consolidated payout ratio (up from a 30% target previously). For FY2025, based on the projected decline in profit, a 10 yen per share dividend is planned.

• Persistent yen depreciation increases the cost of outsourced production, leading to unavoidable rising product cost ratios and downward pressure on profitability, even with partial mitigation from yen-denominated purchases and proactive foreign exchange hedging strategies.
  • Intensifying price competition in third-party supplied contact lens products creates ongoing challenging operating conditions for this segment.
  • Post-acquisition integration of newly acquired businesses carries execution risk that could prevent the company from capturing expected synergies and revenue improvements.

There is no disclosed question and answer section in the provided transcript.